Neuralstem (CUR) Receives FDA Approval to Commence First ALS Stem Cell Trial
Tweet Send to a Friend
Neuralstem, Inc. (NYSE: CUR) announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


